Mochida Pharmaceutical Co., Ltd. 4534

TSE · Japan · Health Technology

¥3,090.00-90.00 (-2.83%)

Market closed· Oct 2, 2026, 6:30 AM UTC· JPY · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Mochida Pharmaceutical Co., Ltd. 4534

TSE · Japan · Health Technology

¥3,090.00-90.00 (-2.83%)

Market closed· Oct 2, 2026, 6:30 AM UTC· JPY · Data may be delayed

Company news

Yahoo FinanceSep 08, 2026

Assessment of the Pulmonary Arterial Hypertension (PAH) Market 2026-2036 Featuring United Therapeutics, Mochida Pharmaceutical, Johnson & Johnson, Merck, and Gossamer Bio

Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Pulmonary Arterial Hypertension - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. The pulmonary arterial hypertension (PAH) market across the United States, EU4 countries-Germany, France, Italy, and Spain-the United Kingdom, and Japan reached approximately USD 8 billion in 2025. The market is projected to expand at a compound annual growth rate of 6.7% from 2022 to 2036, supported by ri

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.

Prices may be delayed and are for informational purposes only - not investment advice.